NEO250117C30000
- 0.00
- 0.000.00%
NeoGenomics Newsroom
Raymond James Maintains NeoGenomics(NEO.US) With Hold Rating
Needham Maintains NeoGenomics(NEO.US) With Buy Rating, Maintains Target Price $19
Needham Reiterates Buy on NeoGenomics, Maintains $19 Price Target
NeoGenomics Down Over 15%, On Track for Largest Percent Decrease Since December 2023 -- Data Talk
NeoGenomics Shares Are Trading Lower. The Company Announced Its CEO Will Retire Effective the First of April.
Craig-Hallum Maintains NeoGenomics(NEO.US) With Buy Rating
Craig-Hallum Releases a Buy Rating on NeoGenomics (NEO)
NeoGenomics Backs FY Rev $655M-$667M >NEO
NeoGenomics: Tony Zook Will Assume the Role of CEO >NEO
Express News | Neogenomics Inc - Reaffirms Full-Year 2024 Guidance
Express News | Neogenomics Announces Chief Executive Officer Succession
NeoGenomics (NEO) Upgraded to Buy: Here's Why
NeoGenomics Is Maintained at Neutral by B of A Securities
BofA Securities Maintains NeoGenomics(NEO.US) With Hold Rating, Raises Target Price to $19
NeoGenomics Study Highlights CtDNA's Potential To Predict Recurrence In High-Risk Melanoma; RaDaR Sequencing Assay Identifies Molecular Residual Disease Across Broader Patient Range, Enabling Earlier Detection And Prognosis Monitoring
NeoGenomics' Newly Published Study Underscores Potential of CtDNA as a Predictive Tool for Monitoring Patients With High-Risk Melanoma
Strong Week for NeoGenomics (NASDAQ:NEO) Shareholders Doesn't Alleviate Pain of Three-year Loss
NeoGenomics Analyst Ratings
Jefferies Initiates NeoGenomics(NEO.US) With Buy Rating, Announces Target Price $22
NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting